AMBAR in the Media
Find all AMBAR press releases below.
CTAD 2019 (December 6, 2019 | San Diego, Calif. USA)
AAIC 2019 (July 16, 2019 | Los Angeles, Calif., USA)
AD/PD 2019 (March 29, 2019 | Lisboa, Portugal)
CTAD 2018 (October 27, 2018 | Barcelona, Spain)
CTAD 2015 (November 6, 2015 | Barcelona, Spain)
AMBAR study 2012 launch (July 3, 2012 | Barcelona, Spain)
|28 SEP, 2017||Nature Outlook||Neuroscience: The power of plasma|
|28 SEP, 2017||Nature Outlook||Therapeutic plasma proteins: their incredible potential as a source of health (sponsored)|
It is currently estimated that 35 million people worldwide suffer from Alzheimer's, a figure that continues to grow.
Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's.
The AMBAR hypothesis
AMBAR is an innovative clinical trial aimed at slowing down the progression of Alzheimer's disease through periodic therapeutic plasma exchange.
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?